Head of Molecular Pathology at Dasa Genomics Laboratory Dasa Brazil
Liquid biopsy is revolutionizing precision medicine by offering a non-invasive alternative to traditional tumor biopsies. While its potential continues to grow, global adoption remains limited due to technical and access-related barriers.
In a partnership with AstraZeneca, SOPHiA GENETICS is expanding access to liquid biopsy testing through MSK-ACCESS® powered with SOPHiA DDM™, a best-in-class and decentralized NGS-based assay.
Join this workshop to: Discover how the SOPHiA GENETICS decentralized approach and advanced analytics, supported by large-scale evidence generation studies, enable patient access and robust results; Learn about the clinical impact and utility of MSK-ACCESS® powered with SOPHiA DDM™ in improving outcomes for cancer patients; Explore how decentralized strategies support late-stage pharmaceutical development and drive commercial success in precision medicine.
